<p>Ginkgo Bioworks（紐約證券交易所代碼：DNA - 獲取免費報告）預計將在 2025 年 8 月 7 日星期四市場收盤後發佈其 2025 年第二季度財報。分析師預計 Ginkgo Bioworks 每股收益為（$1.44），季度收入為 4160 萬美元。Ginkgo Bioworks 已將其 2025 財年的指引設定為每股收益。</p>
<p>Ginkgo Bioworks（紐約證券交易所代碼：DNA - 獲取免費報告）最近一次發佈季度財報是在 5 月 6 日星期二。該公司報告的季度每股收益為（$1.58），低於市場共識預期的（$1.23），差距為（$0.35）。Ginkgo Bioworks 的股本回報率為負的 52.35%，淨利潤率為負的 198.84%。該公司在本季度的收入為 4832 萬美元，而分析師的預期為 3870 萬美元。分析師平均預計 Ginkgo Bioworks 在當前財年的每股收益為-$10，下一財年的每股收益為-$6。</p>
<p>獲取 <strong>Ginkgo Bioworks</strong> 的提醒：</p>
<h2>Ginkgo Bioworks 股票表現</h2>
<p>DNA 股票在星期五開盤價為$12.18。該公司的 50 日移動平均價格為$10.05，200 日移動平均價格為$9.35。Ginkgo Bioworks 的 52 周最低價為$5.00，52 周最高價為$16.85。該公司的市值為 7.129 億美元，市盈率為-1.33，貝塔值為 1.50。</p>
<h2>機構投資者對 Ginkgo Bioworks 的看法</h2>
<p>一些對沖基金最近調整了對該公司的持股。Acadian Asset Management LLC 在第一季度購買了 Ginkgo Bioworks 的新頭寸，價值$120,000。高盛集團在第一季度將其在 Ginkgo Bioworks 的持股增加了 25.4%。高盛集團目前擁有 686,767 股該公司的股票，價值$3,915,000，此前在上個季度又購買了 139,126 股。Millennium Management LLC 在第一季度將其在 Ginkgo Bioworks 的持股增加了 113.1%。Millennium Management LLC 目前擁有 1,427,600 股該公司的股票，價值$8,137,000，此前在上個季度又購買了 757,535 股。最後，AQR Capital Management LLC 在第一季度將其在 Ginkgo Bioworks 的持股增加了 322.6%。AQR Capital Management LLC 目前擁有 158,939 股該公司的股票，價值$906,000，此前在上個季度又購買了 121,326 股。機構投資者持有該公司 78.63% 的股票。</p>
<h2>Ginkgo Bioworks 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Ginkgo Bioworks Holdings, Inc 及其子公司在美國開發細胞編程平台。該平台用於編程細胞，以實現生物產品的生產，如新型治療藥物、食品成分和石油衍生化學品。它服務於製藥和生物技術、農業、工業和環境、食品和營養、消費和技術以及政府和國防等行業。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Ginkgo Bioworks</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>PG&amp;E 是人工智能的投資機會嗎？為什麼期權交易者在大舉下注</li>
<li>什麼是股息收割策略，投資者如何從中獲利？</li>
<li>MarketBeat 週迴顧 – 07/28 - 08/01</li>
<li>如何選擇頂級股票</li>
<li>Hims &amp; Hers 會跟隨諾和諾德下跌嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUROQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUROQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Ginkgo Bioworks 嗎？</h2>
<p>在考慮 Ginkgo Bioworks 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Ginkgo Bioworks 並不在名單上。</p>
<p>雖然 Ginkgo Bioworks 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Ginkgo Bioworks（紐約證券交易所代碼：DNA）將於 8 月 7 日發佈 2025 年第二季度財報，分析師預測每股虧損 1.44 美元，收入為 4160 萬美元。該公司此前報告了 2025 年第一季度每股虧損 1.58 美元，未能達到預期。Ginkgo Bioworks 的市值為 7.129 億美元，股本回報率為負 52.35%。機構投資者持有該股票的 78.63%，近期有高盛和千禧年管理等公司進行了大量購買</p>

<p>Ginkgo Bioworks (NYSE:DNA - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Ginkgo Bioworks to post earnings of ($1.44) per share and revenue of $41.60 million for the quarter. Ginkgo Bioworks has set its FY 2025 guidance at EPS.</p>
<div class="lb-trans"><p>Ginkgo Bioworks（紐約證券交易所代碼：DNA - 獲取免費報告）預計將在 2025 年 8 月 7 日星期四市場收盤後發佈其 2025 年第二季度財報。分析師預計 Ginkgo Bioworks 每股收益為（$1.44），季度收入為 4160 萬美元。Ginkgo Bioworks 已將其 2025 財年的指引設定為每股收益。</p>
</div><p>Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. On average, analysts expect Ginkgo Bioworks to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Ginkgo Bioworks（紐約證券交易所代碼：DNA - 獲取免費報告）最近一次發佈季度財報是在 5 月 6 日星期二。該公司報告的季度每股收益為（$1.58），低於市場共識預期的（$1.23），差距為（$0.35）。Ginkgo Bioworks 的股本回報率為負的 52.35%，淨利潤率為負的 198.84%。該公司在本季度的收入為 4832 萬美元，而分析師的預期為 3870 萬美元。分析師平均預計 Ginkgo Bioworks 在當前財年的每股收益為-$10，下一財年的每股收益為-$6。</p>
</div><p>Get <strong>Ginkgo Bioworks</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ginkgo Bioworks</strong> 的提醒：</p>
</div><h2>Ginkgo Bioworks Stock Performance</h2>
<div class="lb-trans"><h2>Ginkgo Bioworks 股票表現</h2>
</div><p>DNA stock opened at $12.18 on Friday. The firm has a 50 day moving average price of $10.05 and a 200-day moving average price of $9.35. Ginkgo Bioworks has a 52-week low of $5.00 and a 52-week high of $16.85. The firm has a market capitalization of $712.90 million, a price-to-earnings ratio of -1.33 and a beta of 1.50.</p>
<div class="lb-trans"><p>DNA 股票在星期五開盤價為$12.18。該公司的 50 日移動平均價格為$10.05，200 日移動平均價格為$9.35。Ginkgo Bioworks 的 52 周最低價為$5.00，52 周最高價為$16.85。該公司的市值為 7.129 億美元，市盈率為-1.33，貝塔值為 1.50。</p>
</div><h2>Institutional Investors Weigh In On Ginkgo Bioworks</h2>
<div class="lb-trans"><h2>機構投資者對 Ginkgo Bioworks 的看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in Ginkgo Bioworks in the 1st quarter worth $120,000. Goldman Sachs Group Inc. lifted its stake in Ginkgo Bioworks by 25.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after purchasing an additional 139,126 shares in the last quarter. Millennium Management LLC lifted its stake in Ginkgo Bioworks by 113.1% in the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Ginkgo Bioworks by 322.6% in the 1st quarter. AQR Capital Management LLC now owns 158,939 shares of the company's stock worth $906,000 after purchasing an additional 121,326 shares in the last quarter. Institutional investors own 78.63% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近調整了對該公司的持股。Acadian Asset Management LLC 在第一季度購買了 Ginkgo Bioworks 的新頭寸，價值$120,000。高盛集團在第一季度將其在 Ginkgo Bioworks 的持股增加了 25.4%。高盛集團目前擁有 686,767 股該公司的股票，價值$3,915,000，此前在上個季度又購買了 139,126 股。Millennium Management LLC 在第一季度將其在 Ginkgo Bioworks 的持股增加了 113.1%。Millennium Management LLC 目前擁有 1,427,600 股該公司的股票，價值$8,137,000，此前在上個季度又購買了 757,535 股。最後，AQR Capital Management LLC 在第一季度將其在 Ginkgo Bioworks 的持股增加了 322.6%。AQR Capital Management LLC 目前擁有 158,939 股該公司的股票，價值$906,000，此前在上個季度又購買了 121,326 股。機構投資者持有該公司 78.63% 的股票。</p>
</div><h2>Ginkgo Bioworks Company Profile</h2>
<div class="lb-trans"><h2>Ginkgo Bioworks 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings, Inc 及其子公司在美國開發細胞編程平台。該平台用於編程細胞，以實現生物產品的生產，如新型治療藥物、食品成分和石油衍生化學品。它服務於製藥和生物技術、農業、工業和環境、食品和營養、消費和技術以及政府和國防等行業。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Ginkgo Bioworks</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Is PG&amp;E an AI Power Play? Why Options Traders Are Betting Big</li>
<li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
<li>How to Choose Top Rated Stocks</li>
<li>Will Hims &amp; Hers Fall Along With Novo Nordisk?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Ginkgo Bioworks</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>PG&amp;E 是人工智能的投資機會嗎？為什麼期權交易者在大舉下注</li>
<li>什麼是股息收割策略，投資者如何從中獲利？</li>
<li>MarketBeat 週迴顧 – 07/28 - 08/01</li>
<li>如何選擇頂級股票</li>
<li>Hims &amp; Hers 會跟隨諾和諾德下跌嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUROQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=DNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ginkgo Bioworks Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Ginkgo Bioworks 嗎？</h2>
</div><p>Before you consider Ginkgo Bioworks, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ginkgo Bioworks 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Ginkgo Bioworks 並不在名單上。</p>
</div><p>While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ginkgo Bioworks 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Ginkgo Bioworks (DNA) 預計將在週四發佈財報